Type 2 Diabetes Mellitus Not at Glycemic Goal on Metformin: The Next Treatment Step

Clinical Scenario

Adults with type 2 diabetes who have initiated lifestyle modification and first-line metformin but have not achieved or maintained their individualized glycemic goal.

Why Escalation Is Indicated

The first-line regimen — healthy lifestyle behaviors, diabetes self-management education and support, and metformin as initial pharmacotherapy — did not achieve or maintain the individualized glycemic target (A1C below 7%). Failure to reach this goal is the trigger for escalation to the next treatment line.

Next-Line Approach (Overview)

The protocol involves continuing metformin and adding a second glucose-lowering agent — dual-combination therapy. The selection of that agent is guided by the complete clinical picture; several distinct classes are supported by current evidence.

Clinical Goal

Achievement and maintenance of the individualized glycemic goal, with A1C below 7% as the general benchmark.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.2337/dc26-S009

When A1C is ≥1.5% above the individualized glycemic goal, many individuals will require dual-combination therapy or a more potent glucose-lowering agent to achieve and maintain their goal A1C level.

Consider combination therapy in adults with type 2 diabetes for initial treatment to shorten time to attainment of individualized glycemic goals.

View source ↗